1368488
2015
1
heidelberg-university-faculty-of-medicine
50
creator
asc
year
1
227
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22QG8E5748%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Amarsy-Guerle%20et%20al.%22%2C%22parsedDate%22%3A%222015%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAmarsy-Guerle%2C%20R.%2C%20Mougari%2C%20F.%2C%20Jacquier%2C%20H.%2C%20Oliary%2C%20J.%2C%20Benmansour%2C%20H.%2C%20Riahi%2C%20J.%2C%20Ber%26%23xE7%3Bot%2C%20B.%2C%20Raskine%2C%20L.%20and%20Cambau%2C%20E.%20%282015%29.%20%3Cb%3EHigh%20medical%20impact%20of%20implementing%20the%20new%20polymeric%20bead-based%20BacT%5C%2FALERT%26%23xAE%3B%20FAPlus%20and%20FNPlus%20blood%20culture%20bottles%20in%20standard%20care%3C%5C%2Fb%3E.%20European%20Journal%20of%20Clinical%20Microbiology%20%26amp%3B%20Infectious%20Diseases%20%3Ci%3E34%3C%5C%2Fi%3E%2C%201031%26%23x2013%3B1037%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10096-015-2319-8%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10096-015-2319-8%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22High%20medical%20impact%20of%20implementing%20the%20new%20polymeric%20bead-based%20BacT%5C%2FALERT%5Cu00ae%20FAPlus%20and%20FNPlus%20blood%20culture%20bottles%20in%20standard%20care%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Amarsy-Guerle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Jacquier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Oliary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Benmansour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Riahi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Ber%5Cu00e7ot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Raskine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%225%5C%2F2015%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10096-015-2319-8%22%2C%22ISSN%22%3A%220934-9723%2C%201435-4373%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Flink.springer.com%5C%2F10.1007%5C%2Fs10096-015-2319-8%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-02-26T17%3A56%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22K4IIZ9IX%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bernard%20et%20al.%22%2C%22parsedDate%22%3A%222015-03-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBernard%2C%20C.%2C%20Veziris%2C%20N.%2C%20Brossier%2C%20F.%2C%20Sougakoff%2C%20W.%2C%20Jarlier%2C%20V.%2C%20Robert%2C%20J.%20and%20Aubry%2C%20A.%20%282015%29.%20%3Cb%3EMolecular%20Diagnosis%20of%20Fluoroquinolone%20Resistance%20in%20Mycobacterium%20tuberculosis%3C%5C%2Fb%3E.%20Antimicrob%20Agents%20Chemother%20%3Ci%3E59%3C%5C%2Fi%3E%2C%201519%26%23x2013%3B1524%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.04058-14%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.04058-14%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Molecular%20Diagnosis%20of%20Fluoroquinolone%20Resistance%20in%20Mycobacterium%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%5D%2C%22abstractNote%22%3A%22As%20a%20consequence%20of%20the%20use%20of%20fluoroquinolones%20%28FQ%29%2C%20resistance%20to%20FQ%20has%20emerged%2C%20leading%20to%20cases%20of%20nearly%20untreatable%20and%20extensively%20drug-resistant%20tuberculosis.%20Mutations%20in%20DNA%20gyrase%20represent%20the%20main%20mechanism%20of%20FQ%20resistance.%20A%20full%20understanding%20of%20the%20pattern%20of%20mutations%20found%20in%20FQ-resistant%20%28FQr%29%20clinical%20isolates%2C%20and%20of%20their%20proportions%2C%20is%20crucial%20for%20improving%20molecular%20methods%20for%20the%20detection%20of%20FQ%20resistance%20in%20Mycobacterium%20tuberculosis.%20In%20this%20study%2C%20we%20reviewed%20the%20detection%20of%20FQ%20resistance%20in%20isolates%20addressed%20to%20the%20French%20National%20Reference%20Center%20for%20Mycobacteria%20from%202007%20to%202012%2C%20with%20the%20aim%20of%20evaluating%20the%20performance%20of%20PCR%20sequencing%20in%20a%20real-life%20context.%20gyrA%20and%20gyrB%20sequencing%2C%20performed%20prospectively%20on%20M.%20tuberculosis%20clinical%20isolates%2C%20was%20compared%20for%20FQ%20susceptibility%20to%202%20mg%5C%2Fliter%20ofloxacin%20by%20the%20reference%20proportion%20method.%20A%20total%20of%20605%20isolates%2C%20of%20which%2050%25%20were%20multidrug%20resistant%2C%20were%20analyzed.%20The%20increase%20in%20FQr%20strains%20among%20multidrug-resistant%20%28MDR%29%20strains%20during%20the%20time%20of%20the%20study%20was%20alarming%20%288%25%20to%2030%25%29.%20The%20majority%20%2878%25%29%20of%20the%20isolates%20with%20gyrA%20mutations%20were%20FQr%2C%20whereas%20only%2036%25%20of%20those%20with%20gyrB%20mutations%20were%20FQr.%20Only%2012%25%20of%20the%20FQr%20isolates%20had%20a%20single%20mutation%20in%20gyrB.%20Combined%20gyrA%20and%20gyrB%20sequencing%20led%20to%20%3E93%25%20sensitivity%20for%20detecting%20resistance.%20The%20analysis%20of%20the%20four%20false-positive%20and%20the%20five%20false-negative%20results%20of%20gyrA%20and%20gyrB%20sequencing%20illustrated%20the%20actual%20limitations%20of%20the%20reference%20proportion%20method.%20Our%20data%20emphasize%20the%20need%20for%20combined%20gyrA%20and%20gyrB%20sequencing%20in%20the%20investigation%20of%20FQ%20susceptibility%20in%20M.%20tuberculosis%20and%20challenge%20the%20validity%20of%20the%20current%20phenotype-based%20approach%20as%20the%20diagnostic%20gold%20standard%20for%20determining%20FQ%20resistance.%22%2C%22date%22%3A%222015-03-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.04058-14%22%2C%22ISSN%22%3A%220066-4804%2C%201098-6596%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Faac.asm.org%5C%2Fcontent%5C%2F59%5C%2F3%5C%2F1519%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-02-26T18%3A04%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22JHKFH9H7%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brossier%20et%20al.%22%2C%22parsedDate%22%3A%222015%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBrossier%2C%20F.%2C%20Sola%2C%20C.%2C%20Bernard%2C%20C.%2C%20Jarlier%2C%20V.%2C%20Veziris%2C%20N.%20and%20Sougakoff%2C%20W.%20%282015%29.%20%3Cb%3ECharacterization%20of%20a%20Clone%20of%20Mycobacterium%20tuberculosis%20Clinical%20Isolates%20with%20Mutations%20in%20KatG%20%28A110V%29%2C%20EthA%20%28Q269STOP%29%2C%20and%20the%20%3Ci%3EinhA%3C%5C%2Fi%3E%20Promoter%20%28%26%23x2212%3B15C%26%23x2192%3BT%29%3C%5C%2Fb%3E%20Ed.%20Land%2C%20G.%20A.%20Journal%20of%20Clinical%20Microbiology%20%3Ci%3E53%3C%5C%2Fi%3E%2C%203104%26%23x2013%3B3104%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FJCM.01537-15%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FJCM.01537-15%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Characterization%20of%20a%20Clone%20of%20Mycobacterium%20tuberculosis%20Clinical%20Isolates%20with%20Mutations%20in%20KatG%20%28A110V%29%2C%20EthA%20%28Q269STOP%29%2C%20and%20the%20%3Ci%3EinhA%3C%5C%2Fi%3E%20Promoter%20%28%5Cu221215C%5Cu2192T%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Sola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22editor%22%2C%22firstName%22%3A%22G.%20A.%22%2C%22lastName%22%3A%22Land%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2209%5C%2F2015%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1128%5C%2FJCM.01537-15%22%2C%22ISSN%22%3A%220095-1137%2C%201098-660X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjcm.asm.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1128%5C%2FJCM.01537-15%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-02-26T18%3A04%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22ZP2XJUXK%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brossier%20et%20al.%22%2C%22parsedDate%22%3A%222015%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBrossier%2C%20F.%2C%20Sougakoff%2C%20W.%2C%20Bernard%2C%20C.%2C%20Petrou%2C%20M.%2C%20Adeyema%2C%20K.%2C%20Pham%2C%20A.%2C%20Amy%20de%20la%20Breteque%2C%20D.%2C%20Vallet%2C%20M.%2C%20Jarlier%2C%20V.%2C%20Sola%2C%20C.%20and%20Veziris%2C%20N.%20%282015%29.%20%3Cb%3EMolecular%20Analysis%20of%20the%20%3Ci%3EembCAB%3C%5C%2Fi%3E%20Locus%20and%20%3Ci%3EembR%3C%5C%2Fi%3E%20Gene%20Involved%20in%20Ethambutol%20Resistance%20in%20Clinical%20Isolates%20of%20Mycobacterium%20tuberculosis%20in%20France%3C%5C%2Fb%3E.%20Antimicrobial%20Agents%20and%20Chemotherapy%20%3Ci%3E59%3C%5C%2Fi%3E%2C%204800%26%23x2013%3B4808%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00150-15%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00150-15%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Molecular%20Analysis%20of%20the%20%3Ci%3EembCAB%3C%5C%2Fi%3E%20Locus%20and%20%3Ci%3EembR%3C%5C%2Fi%3E%20Gene%20Involved%20in%20Ethambutol%20Resistance%20in%20Clinical%20Isolates%20of%20Mycobacterium%20tuberculosis%20in%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Petrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karine%22%2C%22lastName%22%3A%22Adeyema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane%22%2C%22lastName%22%3A%22Amy%20de%20la%20Breteque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Vallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Sola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2208%5C%2F2015%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.00150-15%22%2C%22ISSN%22%3A%220066-4804%2C%201098-6596%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Faac.asm.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1128%5C%2FAAC.00150-15%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-02-26T18%3A04%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22M8C4879E%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bui%20et%20al.%22%2C%22parsedDate%22%3A%222015%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBui%2C%20T.%20V.%2C%20L%26%23xE9%3Bvy-Bruhl%2C%20D.%2C%20Che%2C%20D.%2C%20Antoine%2C%20D.%2C%20Jarlier%2C%20V.%20and%20Robert%2C%20J.%20%282015%29.%20%3Cb%3EImpact%20of%20the%20BCG%20vaccination%20policy%20on%20tuberculous%20meningitis%20in%20children%20under%206%20years%20in%20metropolitan%20France%20between%202000%20and%202011%3C%5C%2Fb%3E.%20Euro%20Surveill%20%3Ci%3E20%3C%5C%2Fi%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20the%20BCG%20vaccination%20policy%20on%20tuberculous%20meningitis%20in%20children%20under%206%20years%20in%20metropolitan%20France%20between%202000%20and%202011%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20V.%22%2C%22lastName%22%3A%22Bui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22L%5Cu00e9vy-Bruhl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Che%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Antoine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Robert%22%7D%5D%2C%22abstractNote%22%3A%22In%20France%2C%20Bacillus%20Calmette%5Cu2013Gu%5Cu00e9rin%20%28BCG%29%20vaccination%20by%20multipuncture%20device%20was%20withdrawn%20in%202006.%20In%202007%2C%20universal%20mandatory%20BCG%20vaccination%20was%20replaced%20by%20vaccination%20of%20high-risk%20children.%20To%20evaluate%20the%20impact%20of%20these%20changes%20on%20tuberculous%20meningitis%20%28TBM%29%20epidemiology%2C%20data%20on%20culture-positive%20and%20culture-negative%20%28or%20unknown%20microbiological%20result%29%20TBM%20in%20%5Cu22645%20years%20olds%20were%20collected%20from%202000%5Cu20132011.%20Ten%20culture-positive%20and%2017%20culture-negative%20TBM%20cases%20were%20identified%2C%20with%20an%20annual%20incidence%20rate%20ranging%20from%200.16%20to%200.66%20cases%20per%2010%20million%20inhabitants.%20The%20average%20annual%20numbers%20of%20TBM%20cases%20were%202.7%20and%201.8%20from%202000%5Cu20132005%20and%202006%5Cu20132011%2C%20respectively.%20In%20Ile-de-France%20where%20all%20children%20are%20considered%20at%20risk%2C%20the%20overall%20incidence%20rates%20were%201.14%20and%200.29%20per%20million%20for%20the%20two%20periods.%20In%20other%20regions%20where%20only%20at-risk%20children%20are%20vaccinated%20since%202007%2C%20rates%20were%200.30%20and%200.47%2C%20respectively.%20None%20of%20these%20differences%20were%20significant.%20Annual%20incidence%20rates%20for%20each%20one%20year%20age%20group%20cohort%20were%20comparable%20before%20and%20after%20changes.%20Childhood%20TBM%20remains%20rare%20in%20France.%20No%20increase%20in%20incidence%20was%20observed%20after%20changes%20in%20BCG%20vaccination%20strategy.%20Ongoing%20surveillance%20should%20be%20maintained%2C%20as%20a%20slight%20increase%20in%20TBM%20in%20the%20coming%20years%20remains%20possible%2C%20in%20the%20context%20of%20suboptimal%20vaccination%20coverage%20of%20high-risk%20children.%22%2C%22date%22%3A%222015%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%221560-7917%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-04-27T19%3A39%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22H9WA64GZ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cambau%20et%20al.%22%2C%22parsedDate%22%3A%222015-03-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECambau%2C%20E.%2C%20Viveiros%2C%20M.%2C%20Machado%2C%20D.%2C%20Raskine%2C%20L.%2C%20Ritter%2C%20C.%2C%20Tortoli%2C%20E.%2C%20Matthys%2C%20V.%2C%20Hoffner%2C%20S.%2C%20Richter%2C%20E.%2C%20Perez%20Del%20Molino%2C%20M.%20L.%2C%20Cirillo%2C%20D.%20M.%2C%20van%20Soolingen%2C%20D.%20and%20Bottger%2C%20E.%20C.%20%282015%29.%20%3Cb%3ERevisiting%20susceptibility%20testing%20in%20MDR-TB%20by%20a%20standardized%20quantitative%20phenotypic%20assessment%20in%20a%20European%20multicentre%20study%3C%5C%2Fb%3E.%20Journal%20of%20Antimicrobial%20Chemotherapy%20%3Ci%3E70%3C%5C%2Fi%3E%2C%20686%26%23x2013%3B696%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdku438%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdku438%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Revisiting%20susceptibility%20testing%20in%20MDR-TB%20by%20a%20standardized%20quantitative%20phenotypic%20assessment%20in%20a%20European%20multicentre%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Viveiros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Raskine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Ritter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Tortoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Matthys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Hoffner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Richter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Perez%20Del%20Molino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20M.%22%2C%22lastName%22%3A%22Cirillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22van%20Soolingen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20C.%22%2C%22lastName%22%3A%22Bottger%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222015-03-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fjac%5C%2Fdku438%22%2C%22ISSN%22%3A%220305-7453%2C%201460-2091%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.jac.oxfordjournals.org%5C%2Fcgi%5C%2Fdoi%5C%2F10.1093%5C%2Fjac%5C%2Fdku438%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-02-26T17%3A56%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22DBT6PGEE%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Catho%20et%20al.%22%2C%22parsedDate%22%3A%222015%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECatho%2C%20G.%2C%20Couraud%2C%20S.%2C%20Grard%2C%20S.%2C%20Bouaziz%2C%20A.%2C%20S%26%23xE9%3Bn%26%23xE9%3Bchal%2C%20A.%2C%20Valour%2C%20F.%2C%20Perpoint%2C%20T.%2C%20Braun%2C%20E.%2C%20Biron%2C%20F.%2C%20Ferry%2C%20T.%2C%20Chidiac%2C%20C.%2C%20Freymond%2C%20N.%2C%20Perrot%2C%20E.%2C%20Souquet%2C%20P.-J.%2C%20Maury%2C%20J.-M.%2C%20Tronc%2C%20F.%2C%20Veziris%2C%20N.%2C%20Lina%2C%20G.%2C%20Dumitrescu%2C%20O.%20and%20Ader%2C%20F.%20%282015%29.%20%3Cb%3EManagement%20of%20emerging%20multidrug-resistant%20tuberculosis%20in%20a%20low-prevalence%20setting%3C%5C%2Fb%3E.%20Clinical%20Microbiology%20and%20Infection%20%3Ci%3E21%3C%5C%2Fi%3E%2C%20472.e7-472.e10%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2014.12.022%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2014.12.022%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Management%20of%20emerging%20multidrug-resistant%20tuberculosis%20in%20a%20low-prevalence%20setting%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Catho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Couraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Grard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Bouaziz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22S%5Cu00e9n%5Cu00e9chal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Valour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Perpoint%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Braun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Biron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Ferry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chidiac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Freymond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Perrot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.-J.%22%2C%22lastName%22%3A%22Souquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-M.%22%2C%22lastName%22%3A%22Maury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Tronc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Lina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Dumitrescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Ader%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2205%5C%2F2015%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cmi.2014.12.022%22%2C%22ISSN%22%3A%221198743X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS1198743X15001767%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-02-26T17%3A51%3A07Z%22%7D%7D%2C%7B%22key%22%3A%227FHR7W58%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Coolen%20et%20al.%22%2C%22parsedDate%22%3A%222015%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECoolen%2C%20N.%2C%20Morand%2C%20P.%2C%20Martin%2C%20C.%2C%20Hubert%2C%20D.%2C%20Kanaan%2C%20R.%2C%20Chapron%2C%20J.%2C%20Honor%26%23xE9%3B%2C%20I.%2C%20Dusser%2C%20D.%2C%20Audureau%2C%20E.%2C%20Veziris%2C%20N.%20and%20Burgel%2C%20P.-R.%20%282015%29.%20%3Cb%3EReduced%20risk%20of%20nontuberculous%20mycobacteria%20in%20cystic%20fibrosis%20adults%20receiving%20long-term%20azithromycin%3C%5C%2Fb%3E.%20Journal%20of%20Cystic%20Fibrosis%20%3Ci%3E14%3C%5C%2Fi%3E%2C%20594%26%23x2013%3B599%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jcf.2015.02.006%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jcf.2015.02.006%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Reduced%20risk%20of%20nontuberculous%20mycobacteria%20in%20cystic%20fibrosis%20adults%20receiving%20long-term%20azithromycin%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Coolen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Morand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Hubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reem%22%2C%22lastName%22%3A%22Kanaan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeanne%22%2C%22lastName%22%3A%22Chapron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Honor%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Dusser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Audureau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-R%5Cu00e9gis%22%2C%22lastName%22%3A%22Burgel%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2209%5C%2F2015%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jcf.2015.02.006%22%2C%22ISSN%22%3A%2215691993%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS1569199315000466%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-03-26T17%3A56%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22FFFWDEIV%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Grard%20et%20al.%22%2C%22parsedDate%22%3A%222015%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGrard%2C%20S.%2C%20Catho%2C%20G.%2C%20Valour%2C%20F.%2C%20Bouaziz%2C%20A.%2C%20Perpoint%2C%20T.%2C%20Braun%2C%20E.%2C%20Biron%2C%20F.%2C%20Miailhes%2C%20P.%2C%20Ferry%2C%20T.%2C%20Chidiac%2C%20C.%2C%20Souquet%2C%20P.-J.%2C%20Couraud%2C%20S.%2C%20Lina%2C%20G.%2C%20Goutelle%2C%20S.%2C%20Veziris%2C%20N.%2C%20Dumitrescu%2C%20O.%20and%20Ader%2C%20F.%20%282015%29.%20%3Cb%3ELinezolid%20in%20the%20Starter%20Combination%20for%20Multidrug-Resistant%20Tuberculosis%3A%20Time%20to%20Move%20on%20to%20Group%20Four%3F%3C%5C%2Fb%3E%20Open%20Forum%20Infectious%20Diseases%20%3Ci%3E2%3C%5C%2Fi%3E%2C%20ofv175%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofv175%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofv175%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Linezolid%20in%20the%20Starter%20Combination%20for%20Multidrug-Resistant%20Tuberculosis%3A%20Time%20to%20Move%20on%20to%20Group%20Four%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soazic%22%2C%22lastName%22%3A%22Grard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaud%22%2C%22lastName%22%3A%22Catho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Valour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anissa%22%2C%22lastName%22%3A%22Bouaziz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Perpoint%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Evelyne%22%2C%22lastName%22%3A%22Braun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Biron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Miailhes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tristan%22%2C%22lastName%22%3A%22Ferry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Chidiac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Jean%22%2C%22lastName%22%3A%22Souquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Couraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9rard%22%2C%22lastName%22%3A%22Lina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Goutelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oana%22%2C%22lastName%22%3A%22Dumitrescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Ader%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2212%5C%2F2015%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofv175%22%2C%22ISSN%22%3A%222328-8957%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fofid.oxfordjournals.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1093%5C%2Fofid%5C%2Fofv175%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-02-26T17%3A51%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22FKAFPDF7%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20and%20Robert%22%2C%22parsedDate%22%3A%222015-06-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuglielmetti%2C%20L.%20and%20Robert%2C%20J.%20%282015%29.%20%3Cb%3EB%26%23xE9%3Bdaquiline%26%23xA0%3B%3A%20de%20l%26%23x2019%3Bin%20vitro%20aux%20essais%20cliniques%20d%26%23x2019%3Bun%20nouvel%20antituberculeux%3C%5C%2Fb%3E.%20Journal%20des%20Anti-infectieux%20%3Ci%3E17%3C%5C%2Fi%3E%2C%2060%26%23x2013%3B66%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.antinf.2014.12.003%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.antinf.2014.12.003%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22B%5Cu00e9daquiline%5Cu00a0%3A%20de%20l%5Cu2019in%20vitro%20aux%20essais%20cliniques%20d%5Cu2019un%20nouvel%20antituberculeux%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Robert%22%7D%5D%2C%22abstractNote%22%3A%22La%20tuberculose%20est%20une%20cause%20majeure%20de%20morbidit%5Cu00e9%20et%20mortalit%5Cu00e9%20dans%20le%20monde.%20Le%20contr%5Cu00f4le%20de%20la%20tuberculose%20est%20grev%5Cu00e9%20par%20la%20r%5Cu00e9sistance%20aux%20antituberculeux%2C%20et%20plus%20particuli%5Cu00e8rement%20celle%20%5Cu00e0%20la%20rifampicine%20et%20l%5Cu2019isoniazide.%20La%20b%5Cu00e9daquiline%20est%20la%20premi%5Cu00e8re%20mol%5Cu00e9cule%20d%5Cu2019une%20nouvelle%20classe%20d%5Cu2019antituberculeux%2C%20les%20diarylquinolines%2C%20dont%20le%20m%5Cu00e9canisme%20d%5Cu2019action%20est%20l%5Cu2019inhibition%20de%20l%5Cu2019ATP-synthase%20mycobact%5Cu00e9rienne.%20Dans%20cette%20revue%2C%20nous%20pr%5Cu00e9sentons%20les%20donn%5Cu00e9es%20actuelles%20sur%20la%20b%5Cu00e9daquiline%20dont%20les%20%5Cu00e9tudes%20r%5Cu00e9alis%5Cu00e9es%20avant%20son%20approbation%20par%20les%20agences%20du%20m%5Cu00e9dicament%20aux%20%5Cu00c9tats-Unis%20et%20en%20Europe.%20Apr%5Cu00e8s%20les%20%5Cu00e9tudes%20in%20vitro%20et%20in%20vivo%20dans%20le%20mod%5Cu00e8le%20animal%2C%20nous%20pr%5Cu00e9senterons%20les%20r%5Cu00e9sultats%20obtenus%20en%20clinique%20chez%20l%5Cu2019homme.%20La%20b%5Cu00e9daquiline%20a%20une%20activit%5Cu00e9%20tr%5Cu00e8s%20prometteuse%20in%20vitro%20et%20dans%20les%20mod%5Cu00e8les%20animaux%20contre%20Mycobacterium%20tuberculosis%20mais%20aussi%20contre%20d%5Cu2019autres%20mycobact%5Cu00e9ries%20n%5Cu2019appartenant%20pas%20au%20complexe%20tuberculosis.%20Ces%20r%5Cu00e9sultats%20ont%20%5Cu00e9t%5Cu00e9%20confirm%5Cu00e9s%20dans%20les%20premiers%20essais%20cliniques%20r%5Cu00e9alis%5Cu00e9s%20chez%20des%20patients%20atteints%20par%20tuberculose%20%5Cu00e0%20bacilles%20multir%5Cu00e9sistants%20et%20ultrar%5Cu00e9sistants.%20Toutefois%2C%20dans%20un%20de%20ces%20essais%2C%20il%20a%20%5Cu00e9t%5Cu00e9%20mis%20en%20%5Cu00e9vidence%20une%20surmortalit%5Cu00e9%20dans%20le%20groupe%20des%20patients%20trait%5Cu00e9s%20par%20b%5Cu00e9daquiline.%20Cet%20%5Cu00e9v%5Cu00e9nement%20majeur%20tr%5Cu00e8s%20pr%5Cu00e9occupant%20n%5Cu2019a%20pas%20pu%20%5Cu00eatre%20expliqu%5Cu00e9%20%5Cu00e0%20ce%20jour%2C%20malgr%5Cu00e9%20une%20analyse%20approfondie%20des%20causes%20des%20d%5Cu00e9c%5Cu00e8s.%20La%20b%5Cu00e9daquiline%20est%20le%20premier%20m%5Cu00e9dicament%20avec%20un%20nouveau%20m%5Cu00e9canisme%20d%5Cu2019action%20%5Cu00e0%20%5Cu00eatre%20approuv%5Cu00e9%20pour%20le%20traitement%20de%20la%20tuberculose%20apr%5Cu00e8s%20plus%20de%2040ans.%20De%20futures%20%5Cu00e9tudes%20devront%20permettre%20de%20mieux%20%5Cu00e9valuer%20sa%20place%20dans%20de%20nouvelles%20associations%20qui%20pourraient%20permettre%20soit%20de%20raccourcir%20la%20dur%5Cu00e9e%20du%20traitement%20soit%20une%20meilleure%20efficacit%5Cu00e9%20des%20traitement%20des%20tuberculoses%20%5Cu00e0%20bacilles%20multir%5Cu00e9sistants.%5CnTuberculosis%20is%20a%20major%20cause%20of%20morbidity%20and%20mortality%20worldwide.%20Global%20tuberculosis%20control%20is%20jeopardized%20by%20drug%20resistance%2C%20and%20especially%20multidrug-resistance%20defined%20by%20resistance%20to%20rifampicin%20and%20isoniazid.%20Bedaquiline%20is%20the%20first%20compound%20of%20a%20new%20class%20of%20anti-tuberculosis%20drugs%2C%20the%20diarylquinolines%2C%20which%20act%20by%20inhibiting%20the%20mycobacterial%20ATP%20synthase.%20In%20the%20present%20review%2C%20we%20will%20expose%20the%20current%20knowledge%20regarding%20bedaquiline%20including%20the%20results%20of%20the%20studies%2C%20which%20have%20been%20completed%20prior%20to%20its%20approval%20by%20the%20United%20States%20and%20European%20drug%20agencies.%20After%20in%20vitro%20studies%20and%20in%20vivo%20research%20conducted%20in%20animal%20models%2C%20we%20will%20particularly%20detail%20the%20findings%20of%20clinical%20trials.%20Bedaquiline%20has%20shown%20promising%20activity%20in%20vitro%20and%20in%20the%20animal%20model%20against%20Mycobacterium%20tuberculosis%20isolates%20but%20also%20against%20non-tuberculous%20mycobacteria.%20These%20results%20have%20been%20confirmed%20in%20the%20first%20clinical%20trials%20including%20multidrug-resistant%20and%20extensive%20drug-resistant%20tuberculosis%20patients.%20One%20of%20these%20trials%20reported%20an%20increase%20in%20mortality%20in%20the%20bedaquiline-treated%20arm%2C%20which%20has%20to%20date%20not%20been%20explained%20despite%20thorough%20investigation%20of%20the%20causes%20of%20death.%20Bedaquiline%20is%20the%20first%20drug%20with%20a%20new%20mechanism%20of%20action%20to%20be%20approved%20for%20tuberculosis%20treatment%20after%20more%20than%2040%5Cu00a0years.%20Future%20studies%20will%20better%20define%20its%20role%20inside%20new%20drug%20regimens%20with%20the%20potential%20to%20shorten%20treatment%20or%20achieve%20better%20outcome%20in%20multidrug-resistant%20tuberculosis.%22%2C%22date%22%3A%22June%201%2C%202015%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.antinf.2014.12.003%22%2C%22ISSN%22%3A%222210-6545%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS2210654514000908%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-02T16%3A25%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22D5NBDMRS%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20et%20al.%22%2C%22parsedDate%22%3A%222015%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuglielmetti%2C%20L.%2C%20Mougari%2C%20F.%2C%20Lopes%2C%20A.%2C%20Raskine%2C%20L.%20and%20Cambau%2C%20E.%20%282015%29.%20%3Cb%3EHuman%20infections%20due%20to%20nontuberculous%20mycobacteria%3A%20the%20infectious%20diseases%20and%20clinical%20microbiology%20specialists%26%23x2019%3B%20point%20of%20view%3C%5C%2Fb%3E.%20Future%20Microbiology%20%3Ci%3E10%3C%5C%2Fi%3E%2C%201467%26%23x2013%3B1483%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2217%5C%2Ffmb.15.64%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2217%5C%2Ffmb.15.64%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Human%20infections%20due%20to%20nontuberculous%20mycobacteria%3A%20the%20infectious%20diseases%20and%20clinical%20microbiology%20specialists%5Cu2019%20point%20of%20view%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amanda%22%2C%22lastName%22%3A%22Lopes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Raskine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2209%5C%2F2015%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.2217%5C%2Ffmb.15.64%22%2C%22ISSN%22%3A%221746-0913%2C%201746-0921%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.futuremedicine.com%5C%2Fdoi%5C%2F10.2217%5C%2Ffmb.15.64%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-03-26T17%3A49%3A02Z%22%7D%7D%2C%7B%22key%22%3A%229FTWPRVV%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20et%20al.%22%2C%22parsedDate%22%3A%222015-01-15%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuglielmetti%2C%20L.%2C%20D%26%23xFB%3B%2C%20D.%20L.%2C%20Jachym%2C%20M.%2C%20Henry%2C%20B.%2C%20Martin%2C%20D.%2C%20Caumes%2C%20Eric%2C%20Veziris%2C%20Nicolas%2C%20M%26%23xE9%3Btivier%2C%20N.%2C%20Robert%2C%20J.%2C%20Andrejak%2C%20C.%2C%20Bernard%2C%20C.%2C%20Brossier%2C%20F.%2C%20Chadelat%2C%20K.%2C%20Dautzenberg%2C%20B.%2C%20Jarlier%2C%20V.%2C%20Raskine%2C%20L.%2C%20Rivoire%2C%20B.%2C%20Veziris%2C%20N.%2C%20Appere%2C%20C.%2C%20Assouline%2C%20P.%2C%20Borie%2C%20R.%2C%20Boukari%2C%20L.%2C%20Caseris%2C%20M.%2C%20Caumes%2C%20E.%2C%20Douadi%2C%20Y.%2C%20Dumoulin%2C%20J.%2C%20Duval%2C%20C.%2C%20Faucher%2C%20J.%20F.%2C%20Gallien%2C%20S.%2C%20Godet%2C%20C.%2C%20Grusse%2C%20J.%20L.%2C%20Lopes%2C%20A.%2C%20Meynard%2C%20J.%20L.%2C%20Naccache%2C%20J.%20M.%2C%20Philippe%2C%20B.%2C%20Richaud%2C%20C.%20and%20Saad%2C%20H.%20%282015%29.%20%3Cb%3ECompassionate%20Use%20of%20Bedaquiline%20for%20the%20Treatment%20of%20Multidrug-Resistant%20and%20Extensively%20Drug-Resistant%20Tuberculosis%3A%20Interim%20Analysis%20of%20a%20French%20Cohort%3C%5C%2Fb%3E.%20Clin%20Infect%20Dis%20%3Ci%3E60%3C%5C%2Fi%3E%2C%20188%26%23x2013%3B194%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciu786%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciu786%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Compassionate%20Use%20of%20Bedaquiline%20for%20the%20Treatment%20of%20Multidrug-Resistant%20and%20Extensively%20Drug-Resistant%20Tuberculosis%3A%20Interim%20Analysis%20of%20a%20French%20Cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%20Le%22%2C%22lastName%22%3A%22D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beno%5Cu00eet%22%2C%22lastName%22%3A%22Henry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22M%5Cu00e9tivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Andrejak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Chadelat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Dautzenberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Raskine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Rivoire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Appere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Assouline%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Borie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Boukari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Caseris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Douadi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Dumoulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Duval%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20F.%22%2C%22lastName%22%3A%22Faucher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Gallien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Godet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Le%22%2C%22lastName%22%3A%22Grusse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Lopes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Meynard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Naccache%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Philippe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Richaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Saad%22%7D%5D%2C%22abstractNote%22%3A%22Background.%20Bedaquiline%20is%20a%20new%20antibiotic%20that%20was%20approved%20for%20the%20treatment%20of%20multidrug-resistant%20%28MDR%29%20tuberculosis.%20We%20aimed%20to%20evaluate%20the%20short-term%20microbiological%20efficacy%20and%20the%20tolerability%20profile%20of%20bedaquiline.%5CnMethods.%20We%20performed%20a%20retrospective%20cohort%20study%20among%20patients%20with%20MDR%20tuberculosis%20receiving%20bedaquiline%20for%20compassionate%20use%20between%20January%202010%20and%20July%202013%20and%20evaluated%20at%206%20months%20of%20bedaquiline%20treatment.%5CnResults.%20A%20total%20of%2035%20patients%20with%20MDR%20tuberculosis%20were%20included%20in%20the%20study.%20Nineteen%20%2854%25%29%20had%20extensively%20drug-resistant%20%28XDR%29%20tuberculosis%2C%20and%2014%20%2840%25%29%20had%20isolates%20resistant%20to%20fluoroquinolones%20%28Fqs%29%20or%20second-line%20injectables.%20Bedaquiline%20was%20associated%20with%20a%20median%20of%204%20%28range%2C%202%5Cu20135%29%20other%20drugs%2C%20including%20linezolid%20in%2033%20%2894%25%29%20cases.%20At%206%20months%20of%20bedaquiline%20treatment%2C%20culture%20conversion%20was%20achieved%20in%2028%20of%2029%20%2897%25%29%20cases%20with%20culture-positive%20pulmonary%20tuberculosis%20at%20bedaquiline%20initiation.%20Median%20time%20to%20culture%20conversion%20was%2085%20days%20%28range%2C%208%5Cu2013235%20days%29.%20Variables%20independently%20associated%20with%20culture%20conversion%20were%20treatment%20with%20a%20Fq%20%28P%20%3D%20.01%29%2C%20absence%20of%20lung%20cavities%20%28P%20%3C%20.001%29%2C%20and%20absence%20of%20hepatitis%20C%20virus%20infection%20%28P%20%3D%20.001%29.%20A%20total%20of%207%20patients%20%2820%25%29%20experienced%20a%20%5Cu226560-ms%20increase%20in%20QT%20interval%2C%20leading%20to%20bedaquiline%20discontinuation%20in%202%20%286%25%29%20cases.%20Severe%20liver%20enzyme%20elevation%20occurred%20in%202%20patients%20%286%25%29.%20During%20the%20study%20period%2C%201%20death%20%283%25%29%20occurred%20and%20was%20reported%20as%20unrelated%20to%20tuberculosis%20or%20antituberculosis%20treatment.%5CnConclusions.%20The%20use%20of%20bedaquiline%20combined%20with%20other%20active%20drugs%20has%20the%20potential%20to%20achieve%20high%20culture%20conversion%20rates%20in%20complicated%20MDR%20and%20XDR%20tuberculosis%20cases%2C%20with%20a%20reassuring%20safety%20profile%20at%206%20months%20of%20treatment.%22%2C%22date%22%3A%222015-01-15%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciu786%22%2C%22ISSN%22%3A%221058-4838%2C%201537-6591%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fcid.oxfordjournals.org%5C%2Fcontent%5C%2F60%5C%2F2%5C%2F188%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-03-26T17%3A55%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22VN5MQSXI%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Herv%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222015%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHerv%26%23xE9%3B%2C%20C.%2C%20Bergot%2C%20E.%2C%20Veziris%2C%20N.%20and%20Blanc%2C%20F.-X.%20%282015%29.%20%3Cb%3ELa%20tuberculose%20en%202015%26%23x202F%3B%3A%20du%20diagnostic%20%26%23xE0%3B%20la%20d%26%23xE9%3Btection%20des%20formes%20r%26%23xE9%3Bsistantes%3C%5C%2Fb%3E.%20Revue%20des%20Maladies%20Respiratoires%20%3Ci%3E32%3C%5C%2Fi%3E%2C%20784%26%23x2013%3B790%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.rmr.2015.06.008%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.rmr.2015.06.008%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22La%20tuberculose%20en%202015%20%3A%20du%20diagnostic%20%5Cu00e0%20la%20d%5Cu00e9tection%20des%20formes%20r%5Cu00e9sistantes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Herv%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Bergot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.-X.%22%2C%22lastName%22%3A%22Blanc%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2210%5C%2F2015%22%2C%22language%22%3A%22fr%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.rmr.2015.06.008%22%2C%22ISSN%22%3A%2207618425%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS0761842515002636%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-03-26T17%3A55%3A47Z%22%7D%7D%2C%7B%22key%22%3A%227VS7VHZC%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Isaakidis%20et%20al.%22%2C%22parsedDate%22%3A%222015-08-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EIsaakidis%2C%20P.%2C%20Casas%2C%20E.%20C.%2C%20Das%2C%20M.%2C%20Tseretopoulou%2C%20X.%2C%20Ntzani%2C%20E.%20E.%20and%20Ford%2C%20N.%20%282015%29.%20%3Cb%3ETreatment%20outcomes%20for%20HIV%20and%20MDR-TB%20co-infected%20adults%20and%20children%3A%20systematic%20review%20and%20meta-analysis%3C%5C%2Fb%3E.%20The%20International%20Journal%20of%20Tuberculosis%20and%20Lung%20Disease%20%3Ci%3E19%3C%5C%2Fi%3E%2C%20969%26%23x2013%3B978%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.15.0123%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.15.0123%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Treatment%20outcomes%20for%20HIV%20and%20MDR-TB%20co-infected%20adults%20and%20children%3A%20systematic%20review%20and%20meta-analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Isaakidis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20C.%22%2C%22lastName%22%3A%22Casas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Das%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22X.%22%2C%22lastName%22%3A%22Tseretopoulou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20E.%22%2C%22lastName%22%3A%22Ntzani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Ford%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20incidence%20of%20multidrug-resistant%20tuberculosis%20%28MDR-TB%29%20is%20increasing%20in%20high%20human%20immunodeficiency%20virus%20%28HIV%29%20prevalence%20settings%2C%20with%20high%20associated%20mortality.%20Treatment%20outcomes%20in%20HIV-co-infected%20adults%20and%20children%20are%20poorly%20documented.OBJECTIVE%3A%20To%20systematically%20assess%20treatment%20outcomes%20among%20HIV%5Cu2013MDR-TB%20co-infected%20patients.METHODS%3A%20We%20searched%20two%20databases%20and%20the%20proceedings%20of%20an%20annual%20international%20conference%20up%20to%20November%202014%20for%20studies%20reporting%20on%20major%20clinical%20outcomes%20among%20HIV%5Cu2013MDR-TB-co-infected%20adults%20and%20children%2C%20and%20pooled%20the%20results%20using%20random-effects%20meta-analysis.RESULTS%3A%20Of%204812%20abstracts%20and%20articles%20screened%2C%2030%20studies%20providing%20data%20on%202578%20adults%20and%20147%20children%20were%20included.%20Overall%20pooled%20treatment%20success%20was%2056.9%25%20%2895%25%20confidence%20interval%20%5BCI%5D%2046.2%5Cu201367.6%29%2C%2049.9%25%20%2895%25CI%2038.5%5Cu201361.2%29%20among%20adults%20and%2083.4%25%20%2895%25CI%2074.7%5Cu201392%29%20among%20children.%20Mortality%20was%2038%25%20in%20adults%20%2895%25CI%2028%5Cu201348.1%29%20and%2011.4%25%20%2895%25CI%205.8%5Cu201317.1%29%20in%20children.%20Loss%20to%20follow-up%20was%20higher%20among%20adults%20%2816.1%25%2C%2095%25CI%209%5Cu201323.2%29%20than%20among%20children%20%283.9%25%2C%2095%25CI%200.9%5Cu20136.9%29.%20Adverse%20events%20were%20experienced%20by%20the%20majority%20of%20patients%3B%20however%2C%20this%20was%20inconsistently%20documented.%20The%20use%20of%20fluoroquinolones%2C%20aminoglycosides%20and%20Group%20IV%20drugs%20appeared%20to%20be%20associated%20with%20treatment%20success.CONCLUSION%3A%20The%20proportion%20of%20HIV%5Cu2013MDR-TB-co-infected%20patients%20achieving%20treatment%20success%20was%20similar%20to%20success%20rates%20reported%20among%20MDR-TB%20patients%20in%20general%2C%20regardless%20of%20HIV%20status%3B%20however%2C%20mortality%20was%20higher%2C%20particularly%20among%20adults%2C%20highlighting%20the%20need%20for%20early%20diagnosis%20and%20more%20effective%20treatment%20regimens.%22%2C%22date%22%3A%222015-08-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.15.0123%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-01-08T18%3A11%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22DTZ7F3ZB%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jaubert%20et%20al.%22%2C%22parsedDate%22%3A%222015%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EJaubert%2C%20J.%2C%20Mougari%2C%20F.%2C%20Picot%2C%20S.%2C%20Boukerrou%2C%20M.%2C%20Barau%2C%20G.%2C%20Ali%20Ahmed%2C%20S.-A.%2C%20Raskine%2C%20L.%2C%20Camuset%2C%20G.%2C%20Michault%2C%20A.%2C%20Simac%2C%20C.%20and%20Cambau%2C%20E.%20%282015%29.%20%3Cb%3EA%20case%20of%20postoperative%20breast%20infection%20by%20Mycobacterium%20fortuitum%20associated%20with%20the%20hospital%20water%20supply%3C%5C%2Fb%3E.%20American%20Journal%20of%20Infection%20Control%20%3Ci%3E43%3C%5C%2Fi%3E%2C%20406%26%23x2013%3B408%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ajic.2014.12.023%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ajic.2014.12.023%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20case%20of%20postoperative%20breast%20infection%20by%20Mycobacterium%20fortuitum%20associated%20with%20the%20hospital%20water%20supply%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Jaubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Picot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malik%22%2C%22lastName%22%3A%22Boukerrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georges%22%2C%22lastName%22%3A%22Barau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sitty-Amina%22%2C%22lastName%22%3A%22Ali%20Ahmed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Raskine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Camuset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Michault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Simac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2204%5C%2F2015%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ajic.2014.12.023%22%2C%22ISSN%22%3A%2201966553%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS0196655314014308%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-02-26T17%3A56%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22VA8JMHTG%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kibleur%20and%20Veziris%22%2C%22parsedDate%22%3A%222015-03-23%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKibleur%2C%20Y.%20and%20Veziris%2C%20N.%20%282015%29.%20%3Cb%3EFrench%20Nationwide%20Cohort%20Temporary%20Utilization%20Authorization%20Survey%20of%20GranuPAS%26%23xAE%3B%20in%20MDR-TB%20Patients%3C%5C%2Fb%3E.%20Chemotherapy%20%3Ci%3E60%3C%5C%2Fi%3E%2C%20174%26%23x2013%3B179%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1159%5C%2F000371869%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1159%5C%2F000371869%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22French%20Nationwide%20Cohort%20Temporary%20Utilization%20Authorization%20Survey%20of%20GranuPAS%5Cu00ae%20in%20MDR-TB%20Patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Kibleur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222015-3-23%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1159%5C%2F000371869%22%2C%22ISSN%22%3A%220009-3157%2C%201421-9794%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.karger.com%5C%2F%3Fdoi%3D10.1159%5C%2F000371869%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-03-26T17%3A54%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22SVWG3WRG%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Reibel%20et%20al.%22%2C%22parsedDate%22%3A%222015%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EReibel%2C%20F.%2C%20Cambau%2C%20E.%20and%20Aubry%2C%20A.%20%282015%29.%20%3Cb%3EHistoire%20et%20actualit%26%23xE9%3B%20du%20traitement%20de%20la%20l%26%23xE8%3Bpre%3C%5C%2Fb%3E.%20Journal%20des%20Anti-Infectieux%20%3Ci%3E17%3C%5C%2Fi%3E%2C%2091%26%23x2013%3B98%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.antinf.2015.01.004%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.antinf.2015.01.004%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Histoire%20et%20actualit%5Cu00e9%20du%20traitement%20de%20la%20l%5Cu00e8pre%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Reibel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%5D%2C%22abstractNote%22%3A%22Histoire%20et%20actualit%5Cu00e9%20du%20traitement%20de%20la%20l%5Cu00e8pre%22%2C%22date%22%3A%222015%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.antinf.2015.01.004%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.em-consulte.com%5C%2Farticle%5C%2F1008047%5C%2Fhistoire-et-actualite-du-traitement-de-la-lepre%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222019-04-01T16%3A22%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22EIHIVTCZ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Reibel%20et%20al.%22%2C%22parsedDate%22%3A%222015-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EReibel%2C%20F.%2C%20Cambau%2C%20E.%20and%20Aubry%2C%20A.%20%282015%29.%20%3Cb%3EUpdate%20on%20the%20epidemiology%2C%20diagnosis%2C%20and%20treatment%20of%20leprosy%3C%5C%2Fb%3E.%20M%26%23xE9%3Bdecine%20et%20Maladies%20Infectieuses%20%3Ci%3E45%3C%5C%2Fi%3E%2C%20383%26%23x2013%3B393%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.medmal.2015.09.002%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.medmal.2015.09.002%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Update%20on%20the%20epidemiology%2C%20diagnosis%2C%20and%20treatment%20of%20leprosy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Reibel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Aubry%22%7D%5D%2C%22abstractNote%22%3A%22Leprosy%20is%20an%20infectious%20disease%20that%20has%20now%20been%20reported%20for%20more%20than%202000%20years.%20The%20leprosy%20elimination%20goal%20set%20by%20the%20World%20Health%20Organization%20%28WHO%29%2C%20i.e.%20a%20global%20prevalence%20rate%20%3C%201%20patient%20per%2010%2C000%20population%2C%20was%20achieved%20in%20the%20year%202000%2C%20but%20more%20than%20200%2C000%20new%20case%20patients%20are%20still%20reported%20each%20year%2C%20particularly%20in%20India%2C%20Brazil%2C%20and%20Indonesia.%20Leprosy%20is%20a%20specific%20infection%3A%20%28i%29%20it%20is%20a%20chronic%20infection%20primarily%20affecting%20the%20skin%20and%20peripheral%20nerves%2C%20%28ii%29%20Mycobacterium%20leprae%20is%20one%20of%20the%20last%20bacterial%20species%20of%20medical%20interest%20that%20cannot%20be%20cultured%20in%20vitro%20%28mainly%20because%20of%20its%20reductive%20genome%20evolution%29%2C%20and%20%28iii%29%20transmission%20and%20pathophysiological%20data%20is%20still%20limited.%20The%20various%20presentations%20of%20the%20disease%20%28Ridley-Jopling%20and%20WHO%20classifications%29%20are%20correlated%20with%20the%20patient%27s%20immune%20response%2C%20bacillary%20load%2C%20and%20by%20the%20delay%20before%20diagnosis.%20Multidrug%20therapy%20%28dapsone%2C%20rifampicin%2C%20with%20or%20without%20clofazimine%29%20has%20been%20recommended%20since%201982%20as%20the%20standard%20treatment%20of%20leprosy%3B%206%20months%20for%20patients%20presenting%20with%20paucibacillary%20leprosy%20and%2012%20months%20for%20patients%20presenting%20with%20multibacillary%20leprosy.%20The%20worldwide%20use%20of%20leprosy%20drugs%20started%20in%20the%201980s%20and%20their%20free%20access%20since%201995%20contributed%20to%20the%20drastic%20decline%20in%20the%20number%20of%20new%20case%20patients.%20Resistant%20strains%20are%20however%20emerging%20despite%20the%20use%20of%20multidrug%20therapy%3B%20identifying%20and%20monitoring%20resistance%20is%20still%20necessary.%22%2C%22date%22%3A%22septembre%202015%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.medmal.2015.09.002%22%2C%22ISSN%22%3A%220399-077X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0399077X1500181X%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-02T16%3A28%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22U4GH9AVW%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Reibel%20et%20al.%22%2C%22parsedDate%22%3A%222015-10-06%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EReibel%2C%20F.%2C%20Chauffour%2C%20A.%2C%20Brossier%2C%20F.%2C%20Jarlier%2C%20V.%2C%20Cambau%2C%20E.%20and%20Aubry%2C%20A.%20%282015%29.%20%3Cb%3ENew%20Insights%20into%20the%20Geographic%20Distribution%20of%20Mycobacterium%20leprae%20SNP%20Genotypes%20Determined%20for%20Isolates%20from%20Leprosy%20Cases%20Diagnosed%20in%20Metropolitan%20France%20and%20French%20Territories%3C%5C%2Fb%3E%20Ed.%20Johnson%2C%20C.%20PLOS%20Neglected%20Tropical%20Diseases%20%3Ci%3E9%3C%5C%2Fi%3E%2C%20e0004141%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0004141%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0004141%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22New%20Insights%20into%20the%20Geographic%20Distribution%20of%20Mycobacterium%20leprae%20SNP%20Genotypes%20Determined%20for%20Isolates%20from%20Leprosy%20Cases%20Diagnosed%20in%20Metropolitan%20France%20and%20French%20Territories%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Reibel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22editor%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Johnson%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222015-10-6%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pntd.0004141%22%2C%22ISSN%22%3A%221935-2735%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fdx.plos.org%5C%2F10.1371%5C%2Fjournal.pntd.0004141%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-03-26T17%3A54%3A10Z%22%7D%7D%2C%7B%22key%22%3A%229W9IFB5M%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Renvois%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222015%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERenvois%26%23xE9%3B%2C%20A.%2C%20Brossier%2C%20F.%2C%20Galati%2C%20E.%2C%20Veziris%2C%20N.%2C%20Sougakoff%2C%20W.%2C%20Aubry%2C%20A.%2C%20Robert%2C%20J.%2C%20Cambau%2C%20E.%2C%20Jarlier%2C%20V.%20and%20Bernard%2C%20C.%20%282015%29.%20%3Cb%3EAssessing%20Primary%20and%20Secondary%20Resistance%20to%20Clarithromycin%20and%20Amikacin%20in%20Infections%20Due%20to%20Mycobacterium%20avium%20Complex%3C%5C%2Fb%3E.%20Antimicrobial%20Agents%20and%20Chemotherapy%20%3Ci%3E59%3C%5C%2Fi%3E%2C%207153%26%23x2013%3B7155%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.01027-15%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.01027-15%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Assessing%20Primary%20and%20Secondary%20Resistance%20to%20Clarithromycin%20and%20Amikacin%20in%20Infections%20Due%20to%20Mycobacterium%20avium%20Complex%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Renvois%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eve%22%2C%22lastName%22%3A%22Galati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bernard%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2211%5C%2F2015%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.01027-15%22%2C%22ISSN%22%3A%220066-4804%2C%201098-6596%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Faac.asm.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1128%5C%2FAAC.01027-15%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-03-26T17%3A47%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22ARQU57G3%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Robert%20and%20CNR-MyRMA%22%2C%22parsedDate%22%3A%222015-03-24%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERobert%2C%20J.%20and%20CNR-MyRMA%20%282015%29.%20%3Cb%3ER%26%23xE9%3Bsistance%20aux%20antituberculeux%20en%20France%20en%202013%3C%5C%2Fb%3E.%20Bulletin%20Epid%26%23xE9%3Bmiologique%20Hebdomadaire%20%3Ci%3E9%26%23x2013%3B10%3C%5C%2Fi%3E%2C%20172%26%23x2013%3B174%2C%20URL%3A%20%3Ca%20class%3D%27zp-ItemURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fwww.invs.sante.fr%5C%2Fbeh%5C%2F2015%5C%2F9-10%5C%2Fpdf%5C%2F2015_9-10_4.pdf%27%3Ehttp%3A%5C%2F%5C%2Fwww.invs.sante.fr%5C%2Fbeh%5C%2F2015%5C%2F9-10%5C%2Fpdf%5C%2F2015_9-10_4.pdf%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22R%5Cu00e9sistance%20aux%20antituberculeux%20en%20France%20en%202013%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22CNR-MyRMA%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2224%20mar%202015%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.invs.sante.fr%5C%2Fbeh%5C%2F2015%5C%2F9-10%5C%2Fpdf%5C%2F2015_9-10_4.pdf%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-04-25T16%3A19%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22SCP4EEUH%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Roux%20et%20al.%22%2C%22parsedDate%22%3A%222015%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERoux%2C%20A.-L.%2C%20Catherinot%2C%20E.%2C%20Soismier%2C%20N.%2C%20Heym%2C%20B.%2C%20Bellis%2C%20G.%2C%20Lemonnier%2C%20L.%2C%20Chiron%2C%20R.%2C%20Fauroux%2C%20B.%2C%20Le%20Bourgeois%2C%20M.%2C%20Munck%2C%20A.%2C%20Pin%2C%20I.%2C%20Sermet%2C%20I.%2C%20Gutierrez%2C%20C.%2C%20Veziris%2C%20N.%2C%20Jarlier%2C%20V.%2C%20Cambau%2C%20E.%2C%20Herrmann%2C%20J.-L.%2C%20Guillemot%2C%20D.%20and%20Gaillard%2C%20J.-L.%20%282015%29.%20%3Cb%3EComparing%20Mycobacterium%20massiliense%20and%20Mycobacterium%20abscessus%20lung%20infections%20in%20cystic%20fibrosis%20patients%3C%5C%2Fb%3E.%20Journal%20of%20Cystic%20Fibrosis%20%3Ci%3E14%3C%5C%2Fi%3E%2C%2063%26%23x2013%3B69%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jcf.2014.07.004%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jcf.2014.07.004%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparing%20Mycobacterium%20massiliense%20and%20Mycobacterium%20abscessus%20lung%20infections%20in%20cystic%20fibrosis%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Laure%22%2C%22lastName%22%3A%22Roux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Catherinot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Soismier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beate%22%2C%22lastName%22%3A%22Heym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gil%22%2C%22lastName%22%3A%22Bellis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydie%22%2C%22lastName%22%3A%22Lemonnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rapha%5Cu00ebl%22%2C%22lastName%22%3A%22Chiron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitte%22%2C%22lastName%22%3A%22Fauroux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Le%20Bourgeois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Munck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Pin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Sermet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Gutierrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Louis%22%2C%22lastName%22%3A%22Herrmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Guillemot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Louis%22%2C%22lastName%22%3A%22Gaillard%22%7D%5D%2C%22abstractNote%22%3A%22Background%5CnMycobacterium%20massiliense%20is%20closely%20related%20to%20Mycobacterium%20abscessus%20and%20is%20also%20a%20frequent%20cause%20of%20mycobacterial%20lung%20disease%20in%20patients%20with%20cystic%20fibrosis%20%28CF%29.%20There%20has%20been%20no%20previous%20investigation%20of%20possible%20differences%20between%20M.%20massiliense%20and%20M.%20abscessus%20infections%20in%20the%20setting%20of%20CF.%5CnMethods%5CnWe%20studied%20a%20prospective%20cohort%20of%2016%20M.%20massiliense%20and%2027%20M.%20abscessus%20lung%20infection%20cases%20with%20CF%2C%20with%20a%20mean%20follow-up%20of%206%5Cu2005years.%5CnResults%5CnM.%20massiliense%20cases%20were%20younger%20than%20M.%20abscessus%20cases%20%28mean%20age%3A%2012.8%20vs%2017.1%5Cu2005years%3B%20p%5Cu2005%3D%5Cu20050.02%29%20at%20the%20time%20of%20the%20first%20mycobacterial%20isolation%20and%20also%20had%20lower%20body%20mass%20index%20values%20%28mean%3A%2016.4%20vs%2019.3%5Cu2005kg%5C%2Fm2%2C%20p%5Cu2005%3D%5Cu20050.002%29.%20All%20M.%20massiliense%20cases%2C%20except%20one%2C%20had%20negative%20BMI%20Z-score%20values%20at%20the%20time%20of%20the%20first%20mycobacterial%20isolation%20%2811%5C%2F12%20vs%2016%5C%2F23%20M.%20abscessus%20cases%2C%20p%5Cu2005%3D%5Cu20050.04%29.%20Clarithromycin-based%20combination%20therapies%20led%20to%20mycobacterial%20eradication%20in%20100%25%20of%20M.%20massiliense%20cases%20but%20only%20in%2027%25%20of%20M.%20abscessus%20cases%20%28p%5Cu2005%3D%5Cu20050.009%29.%5CnConclusion%5CnOur%20data%20show%20a%20particular%20link%20between%20M.%20massiliense%20and%20malnutrition%20specifically%20in%20CF%20patients.%20Unlike%20M.%20abscessus%2C%20the%20bacteriological%20response%20of%20M.%20massiliense%20to%20combination%20antibiotic%20therapies%20containing%20clarithromycin%20was%20excellent.%20Distinguishing%20between%20M.%20massiliense%20and%20M.%20abscessus%20has%20major%20clinical%20implications%20for%20CF%20patients.%22%2C%22date%22%3A%222015%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jcf.2014.07.004%22%2C%22ISSN%22%3A%221569-1993%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.cysticfibrosisjournal.com%5C%2Farticle%5C%2FS1569199314001659%5C%2Fabstract%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-09-08T15%3A58%3A39Z%22%7D%7D%5D%7D
Amarsy-Guerle, R., Mougari, F., Jacquier, H., Oliary, J., Benmansour, H., Riahi, J., Berçot, B., Raskine, L. and Cambau, E. (2015). High medical impact of implementing the new polymeric bead-based BacT/ALERT® FAPlus and FNPlus blood culture bottles in standard care. European Journal of Clinical Microbiology & Infectious Diseases 34, 1031–1037, http://doi.org/10.1007/s10096-015-2319-8.
Bernard, C., Veziris, N., Brossier, F., Sougakoff, W., Jarlier, V., Robert, J. and Aubry, A. (2015). Molecular Diagnosis of Fluoroquinolone Resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 59, 1519–1524, http://doi.org/10.1128/AAC.04058-14.
Brossier, F., Sola, C., Bernard, C., Jarlier, V., Veziris, N. and Sougakoff, W. (2015). Characterization of a Clone of Mycobacterium tuberculosis Clinical Isolates with Mutations in KatG (A110V), EthA (Q269STOP), and the inhA Promoter (−15C→T) Ed. Land, G. A. Journal of Clinical Microbiology 53, 3104–3104, http://doi.org/10.1128/JCM.01537-15.
Brossier, F., Sougakoff, W., Bernard, C., Petrou, M., Adeyema, K., Pham, A., Amy de la Breteque, D., Vallet, M., Jarlier, V., Sola, C. and Veziris, N. (2015). Molecular Analysis of the embCAB Locus and embR Gene Involved in Ethambutol Resistance in Clinical Isolates of Mycobacterium tuberculosis in France. Antimicrobial Agents and Chemotherapy 59, 4800–4808, http://doi.org/10.1128/AAC.00150-15.
Bui, T. V., Lévy-Bruhl, D., Che, D., Antoine, D., Jarlier, V. and Robert, J. (2015). Impact of the BCG vaccination policy on tuberculous meningitis in children under 6 years in metropolitan France between 2000 and 2011. Euro Surveill 20.
Cambau, E., Viveiros, M., Machado, D., Raskine, L., Ritter, C., Tortoli, E., Matthys, V., Hoffner, S., Richter, E., Perez Del Molino, M. L., Cirillo, D. M., van Soolingen, D. and Bottger, E. C. (2015). Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. Journal of Antimicrobial Chemotherapy 70, 686–696, http://doi.org/10.1093/jac/dku438.
Catho, G., Couraud, S., Grard, S., Bouaziz, A., Sénéchal, A., Valour, F., Perpoint, T., Braun, E., Biron, F., Ferry, T., Chidiac, C., Freymond, N., Perrot, E., Souquet, P.-J., Maury, J.-M., Tronc, F., Veziris, N., Lina, G., Dumitrescu, O. and Ader, F. (2015). Management of emerging multidrug-resistant tuberculosis in a low-prevalence setting. Clinical Microbiology and Infection 21, 472.e7-472.e10, http://doi.org/10.1016/j.cmi.2014.12.022.
Coolen, N., Morand, P., Martin, C., Hubert, D., Kanaan, R., Chapron, J., Honoré, I., Dusser, D., Audureau, E., Veziris, N. and Burgel, P.-R. (2015). Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin. Journal of Cystic Fibrosis 14, 594–599, http://doi.org/10.1016/j.jcf.2015.02.006.
Grard, S., Catho, G., Valour, F., Bouaziz, A., Perpoint, T., Braun, E., Biron, F., Miailhes, P., Ferry, T., Chidiac, C., Souquet, P.-J., Couraud, S., Lina, G., Goutelle, S., Veziris, N., Dumitrescu, O. and Ader, F. (2015). Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four? Open Forum Infectious Diseases 2, ofv175, http://doi.org/10.1093/ofid/ofv175.
Guglielmetti, L. and Robert, J. (2015). Bédaquiline : de l’in vitro aux essais cliniques d’un nouvel antituberculeux. Journal des Anti-infectieux 17, 60–66, http://doi.org/10.1016/j.antinf.2014.12.003.
Guglielmetti, L., Mougari, F., Lopes, A., Raskine, L. and Cambau, E. (2015). Human infections due to nontuberculous mycobacteria: the infectious diseases and clinical microbiology specialists’ point of view. Future Microbiology 10, 1467–1483, http://doi.org/10.2217/fmb.15.64.
Guglielmetti, L., Dû, D. L., Jachym, M., Henry, B., Martin, D., Caumes, Eric, Veziris, Nicolas, Métivier, N., Robert, J., Andrejak, C., Bernard, C., Brossier, F., Chadelat, K., Dautzenberg, B., Jarlier, V., Raskine, L., Rivoire, B., Veziris, N., Appere, C., Assouline, P., Borie, R., Boukari, L., Caseris, M., Caumes, E., Douadi, Y., Dumoulin, J., Duval, C., Faucher, J. F., Gallien, S., Godet, C., Grusse, J. L., Lopes, A., Meynard, J. L., Naccache, J. M., Philippe, B., Richaud, C. and Saad, H. (2015). Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort. Clin Infect Dis 60, 188–194, http://doi.org/10.1093/cid/ciu786.
Hervé, C., Bergot, E., Veziris, N. and Blanc, F.-X. (2015). La tuberculose en 2015 : du diagnostic à la détection des formes résistantes. Revue des Maladies Respiratoires 32, 784–790, http://doi.org/10.1016/j.rmr.2015.06.008.
Isaakidis, P., Casas, E. C., Das, M., Tseretopoulou, X., Ntzani, E. E. and Ford, N. (2015). Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. The International Journal of Tuberculosis and Lung Disease 19, 969–978, http://doi.org/10.5588/ijtld.15.0123.
Jaubert, J., Mougari, F., Picot, S., Boukerrou, M., Barau, G., Ali Ahmed, S.-A., Raskine, L., Camuset, G., Michault, A., Simac, C. and Cambau, E. (2015). A case of postoperative breast infection by Mycobacterium fortuitum associated with the hospital water supply. American Journal of Infection Control 43, 406–408, http://doi.org/10.1016/j.ajic.2014.12.023.
Kibleur, Y. and Veziris, N. (2015). French Nationwide Cohort Temporary Utilization Authorization Survey of GranuPAS® in MDR-TB Patients. Chemotherapy 60, 174–179, http://doi.org/10.1159/000371869.
Reibel, F., Cambau, E. and Aubry, A. (2015). Histoire et actualité du traitement de la lèpre. Journal des Anti-Infectieux 17, 91–98, http://doi.org/10.1016/j.antinf.2015.01.004.
Reibel, F., Cambau, E. and Aubry, A. (2015). Update on the epidemiology, diagnosis, and treatment of leprosy. Médecine et Maladies Infectieuses 45, 383–393, http://doi.org/10.1016/j.medmal.2015.09.002.
Reibel, F., Chauffour, A., Brossier, F., Jarlier, V., Cambau, E. and Aubry, A. (2015). New Insights into the Geographic Distribution of Mycobacterium leprae SNP Genotypes Determined for Isolates from Leprosy Cases Diagnosed in Metropolitan France and French Territories Ed. Johnson, C. PLOS Neglected Tropical Diseases 9, e0004141, http://doi.org/10.1371/journal.pntd.0004141.
Renvoisé, A., Brossier, F., Galati, E., Veziris, N., Sougakoff, W., Aubry, A., Robert, J., Cambau, E., Jarlier, V. and Bernard, C. (2015). Assessing Primary and Secondary Resistance to Clarithromycin and Amikacin in Infections Due to Mycobacterium avium Complex. Antimicrobial Agents and Chemotherapy 59, 7153–7155, http://doi.org/10.1128/AAC.01027-15.
Robert, J. and CNR-MyRMA (2015). Résistance aux antituberculeux en France en 2013. Bulletin Epidémiologique Hebdomadaire 9–10, 172–174, URL: http://www.invs.sante.fr/beh/2015/9-10/pdf/2015_9-10_4.pdf.
Roux, A.-L., Catherinot, E., Soismier, N., Heym, B., Bellis, G., Lemonnier, L., Chiron, R., Fauroux, B., Le Bourgeois, M., Munck, A., Pin, I., Sermet, I., Gutierrez, C., Veziris, N., Jarlier, V., Cambau, E., Herrmann, J.-L., Guillemot, D. and Gaillard, J.-L. (2015). Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients. Journal of Cystic Fibrosis 14, 63–69, http://doi.org/10.1016/j.jcf.2014.07.004.